León-Ortiz AG, Guáman-Crespo JO, Sánchez-Zúñiga MJ, Carrillo-Esper R

Language: Spanish
References: 14
Page: 421-426
PDF size: 408.63 Kb.

ABSTRACT

Wegener’s granulomatosis is a systemic necrotizing vasculitis that affects small and medium vessels, is associated with the expression of cytoplasmic ANCA antibodies. Characteristically disease causes airway injury and glomerulonephritis. Respiratory compromise is expressed as sinusitis, otic and nasal pathology, alveolar hemorrhage, being the most serious manifestation of lung involvement. Kidney damage is not indicative of severity, but it is of prognosis, so it is recommended to do a renal biopsy at the time of diagnosis of the disease. Treatment will depend on the severity of the clinical manifestation; it has a phase of remission induction and other of maintenance. In cases of massive alveolar hemorrhage or damage to any other target organ, plasmapheresis should be considered, as it has proven be highly effective in terms of remission.

REFERENCES

1. Kubaisi B, Abu Samra K, Foster CS. Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations. Intractable Rare Dis Res 2016;5:61-69.

2. Wojciechowska J, Krajewski W, Krajewski P, Kręcicki T. Granulomatosis with polyangiitis in otolaryngologist practice: A review of current knowledge. Clin Exp Otorhinolaryngol 2016;9:8-13.

3. Comarmond C, Crestani B, Tazi A, Hervier B, Adam- Marchand S, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine 2014 Nov;93:340-349.

4. Bonatti F, Reina M, Neri TM, Martorana D. Genetic susceptibility to ANCA-associated vasculitis: State of the art. Front Immunol 2014;5:1-14.

5. Monach PA. Biomarkers in vasculitis. Curr Opin Rheumatol 2014;26:24-30.

6. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-1107.

7. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17.

8. Trimarchi M, Sinico RA, Teggi R, Bussi M, Specks U, Meroni PL. Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev 2013;12:501-505.

9. Dufour JF, Le Gallou T, Cordier J-F, Aumaitre O, et al. Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. Medicine 2012;91:67-74.

10. Morales-Angulo C, García-Zornoza R, Obeso-Agüera S, Calvo-Alén J, González-Gay MA. Manifestaciones otorrinolaringológicas en pacientes con granulomatosis de Wegener (granulomatosis con poliangeitis). Acta Otorrinolaringol Esp 2012;63:206-211.

11. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-498.

12. Buendía RI, Navarro C, Rojas-Serrano J. Hemorragia alveolar difusa: causas y desenlaces en un instituto de tercer nivel. Reumatol Clin 2010;6:196-198.

13. Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA. Ocular complications of Wegener's granulomatosis. Ophthalmology 1983;90:279-290.

14. Vera-Lastra O. Granulomatosis de Wegener, abordaje diagnóstico y terapéutico. Gac Méd Méx 2009;146:121-129.